Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 792 of 6351
-
New hope for tough leukemia: experimental drug AZD0486 enters human trials
Disease control Recruiting nowThis is a Phase 1/2, global multicentre, open-label, single-arm, dose escalation and dose optimization study of surovatamig (AZD0486) to evaluate the safety, tolerability, and efficacy of surovatamig (AZD0486) monotherapy in participants with R/R B ALL. The study will consist of …
Phase 1/2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
New inhaled drug shows promise for rare lung disease
Disease control CompletedThe primary objective of the study is to determine the effect of seralutinib on improving exercise capacity in subjects with WHO Group 1 PAH who are FC II or III. The secondary objective for this trial is to determine time to clinical worsening.
Phase 3 • Sponsor: GB002, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New hope for kids with Hard-to-Treat blood disorder
Disease control Recruiting nowTo evaluate the safety and efficacy of Anti-CD38 Antibody in the treatment of pediatric primary immune thrombocytopenia in patients who have not responded adequately or relapsed after first-line treatment and at least one second-line therapy including Anti-CD20 Antibody and/or TP…
Phase 2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Heart zapping vs. pills: which works better for stubborn irregular heartbeat?
Disease control OngoingThe purpose of this study is to establish the safety and effectiveness of pulsed field ablation as a first-line ablation treatment for subjects with persistent atrial fibrillation as compared to subjects who received an initial treatment with anti-arrhythmic drugs.
Sponsor: Boston Scientific Corporation • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New combo therapy targets hard-to-treat endometrial cancer
Disease control Recruiting nowA Phase 2 Multi-center Open-label Trial of nab-Sirolimus in Combination with Letrozole in Advanced or Recurrent Endometrioid Endometrial Cancer
Phase 2 • Sponsor: Aadi Bioscience, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Can a drug duo outsmart a common cancer mutation?
Disease control Stopped earlyThe purpose of this study is to evaluate the safety and tolerability of INCB099280 in combination with adagrasib and to establish the MTD or identify RDE(s) for the combination of INCB099280 and adagrasib.
Phase 1 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New shot could tame rare metabolic disease
Disease control Recruiting nowThe purpose of this study is to measure efficacy and safety of pegtibatinase treatment compared with placebo in participants with classical HCU receiving standard of care. Study details include: * Total Study duration: up to 38 weeks * Screening: * Initial Screening duration:…
Phase 3 • Sponsor: Travere Therapeutics, Inc. • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Radioactive drug targets tough prostate cancer
Disease control Recruiting nowThis phase II trial studies how well lutetium Lu 177 dotatate works in treating patients with prostate cancer with neuroendocrine differentiation that has spread to other places in the body (metastatic). Neuroendocrine differentiation refers to cells that have traits of both horm…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New hope for progressive MS: drug aims to halt worsening disability
Disease control OngoingThe purpose of this randomized, double-blind, placebo-controlled, parallel group study is to determine the efficacy of frexalimab in delaying the disability progression and the safety up to 36 months double-blind administration of study intervention compared to placebo in male an…
Phase 3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Could vitamin c save lives after cardiac arrest? new trial investigates
Disease control Recruiting nowAmong patients admitted after an out-of-hospital cardiac arrest (OHCA) in intensive care unit (ICU), almost two thirds of patients will develop in the first hours a post-cardiac arrest (CA) shock. This post-CA shock, combines cardiac and hemodynamic failure, generally resulting i…
Phase 2 • Sponsor: Centre Hospitalier de Bethune • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New combo aims to fight Drug-Resistant prostate cancer
Disease control Recruiting nowThis is an open-label, multi-site study of apalutamide with carotuximab in patients who have progressed on androgen receptor signaling inhibitor (ARSI) therapy. This study will begin with a safety assessment in the first 10 subjects (part 1: Safety Lead-in). If the combination is…
Phase 2 • Sponsor: Edwin Posadas, MD • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New pill shows promise for rare lung cancer mutations
Disease control Recruiting nowThe main objective of the study will be to evaluate the efficacy of sutetinib maleate capsules in participants with locally advanced or metastatic non-small cell lung cancer NSCLC (uncommon EGFR mutations only).
Phase 2 • Sponsor: Teligene US • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Can a biologic drug quiet the relentless itch of prurigo nodularis?
Disease control OngoingPrurigo nodularis (PN) is a skin disease characterized by the presence of single to multiple symmetrically distributed, intensively itching nodules. The main symptom is uncontrollable itching leading to prolonged, repetitive, and uncontrollable rubbing, scratching which in turn c…
Sponsor: Sanofi • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Can a new biologic tame lupus flares?
Disease control Stopped earlyThe purpose of this study is to evaluate the efficacy and safety of MK-6194 in adult participants with systemic lupus erythematosus.
Phase 2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Placental clues from a past pregnancy may guide treatment to prevent future complications
Disease control Recruiting nowThe goal of this randomized clinical trial is to evaluate if we can use placental pathology in a prior pregnancy which had an adverse outcome, such as early delivery, stillbirth, a baby born smaller than expected, or severe forms of high blood pressure during pregnancy, to guide …
Phase 2 • Sponsor: Endeavor Health • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Gut radiation may revive immunotherapy in resistant cancers
Disease control CompletedPreclinical and clinical studies have shown that intestinal low dose radiotherapy (ILDR) can enhance antitumor immunity and response to immune checkpoint blockade (ICB). Therefore, the investigators launch a phase Ⅱ trial to evaluate the clinical value of combining ILDR and progr…
Phase 2 • Sponsor: Chuangzhen Chen • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
Could stem cells be the key to saving lives from Sepsis-Induced lung failure?
Disease control Recruiting nowThis study was conducted to determine the effect of Umbilical Cord Mesenchymal Stem Cell (UC-MSC) and Secretome in severe ARDS patients. The study is a randomized control trial - double blind, which has 3 arms intervention namely, Control treatment, UC-MSC treatment, and UC-MSC a…
Phase 1/2 • Sponsor: PT. Prodia Stem Cell Indonesia • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Experimental antibody drug shows promise for Hard-to-Treat lymphoma
Disease control CompletedThe goal of this observational study is to evaluate the anti-lymphoma activity of glofitamab, administered according to the Compassionate Use Program, in relapsed/refractory B-NHL patients. The main question it aims to answer is the rate of patients in complete response.
Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
A 5-hour test may replace days of waiting for the right antibiotic in blood infections
Diagnosis CompletedThis study is a 2-arm, multicenter, multinational, prospective, randomized, controlled clinical trial. Hospitalized subjects with blood cultures growing Gram negative bacilli (GNB) will be randomized 1:1 to have the positive blood cultures characterized using standard of care (SO…
Sponsor: Duke University • Aim: Diagnosis
Last updated Jul 30, 2026 00:00 UTC
-
Radiation zaps resistant cancer spots, may extend immunotherapy success
Disease control Recruiting nowThis Phase II trial will evaluate progression-free survival after Stereotactic Body Radiation Therapy to oligoprogressive (1-5) lesions in metastatic renal cell carcinoma patients on any immune checkpoint inhibitor-containing regimen with last dose of systemic therapy within 3 mo…
Phase 2 • Sponsor: Yale University • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC